SkinBioTherapeutics (SBTX; the Group) is a microbiome specialist focused on the development of microbiome-based technologies for skin health. Since IPO on AIM in 2017, the Company has made significant progress into the commercialisation of SkinBiotix®, the Group’s proprietary probiotic cosmetic technology. In November 2019, SBTX struck a commercial deal with the multinational specialty chemicals group, Croda plc (CRDA.L). Croda intends to develop a cosmetic ingredient based on SkinBiotix® techno ....
27 Jan 2020
First deal marks transition to a commercialstage company
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
First deal marks transition to a commercialstage company
SkinBioTherapeutics Plc (SBTX:LON) | 12.8 0.1 5.2% | Mkt Cap: 24.6m
- Published:
27 Jan 2020 -
Author:
Vadim Alexandre | Liam Gascoigne-Cohen -
Pages:
28
SkinBioTherapeutics (SBTX; the Group) is a microbiome specialist focused on the development of microbiome-based technologies for skin health. Since IPO on AIM in 2017, the Company has made significant progress into the commercialisation of SkinBiotix®, the Group’s proprietary probiotic cosmetic technology. In November 2019, SBTX struck a commercial deal with the multinational specialty chemicals group, Croda plc (CRDA.L). Croda intends to develop a cosmetic ingredient based on SkinBiotix® techno ....